Ann: Clinical Trial for BodyGuard Technology, page-109

I think my post is more a reflection of my own frustrations than playing devils advocate.

OBJ has monumental potential, and believe it or not, it can be said to be still "on track" to reach that.

Its just that the "Track" is nothing like what we think it to be, because we are continuously kept in a void of limited information. I understand the need to protect IP , and the client confidentially requirements, but doing so leaves us joining dots.

Now, dot-joining isn't a bad thing, it can and has given us a very strong and reasonable conclusion of whats happening with many companies. It's unfortunate that for OBJ, we often find the dots move, based on new information, and we start over, realizing our time-frames and expectations have all changed again, and again.

The track OBJ is traveling cant be looked at long term anymore, unless your prepared for that long term to be over another 10 years from today. Historically the announcements and subsequent delays have proven that doing so is dangerous, so up to 6 months(or beyond 10 years) is about all you can do for forwarding looking projections of OBJ, as there is always left field announcements which destroy certainty.

So bottom line for me, why i hold, and my deadlines:
B&Y have, several times now, quoted information in their reports, which shows they clearly have a deeper knowledge of the company than the public, as seen in the reports where we find the new track-shifting information. In particular B&Y's Feb 2016 report gave a very reasonable forecast of expected revenue.

OBJ has, and continues to remains on track with this(at this point). So that leads me to believe B&Y knew way back that revenues were way further out than shareholders were anticipating, more about the source of those revenues, and are just riding the P&D waves in the subsequent years.

Given that this report seems to be all that we can get forecast wise (OBJ itself cant, or wont, provide diddly squat in comparison), the report has used privy information behind its reasoning, and remains correct with OBJ performance, I will continue to hold OBJ as long as it can meet this forecast (within reasonable margins).

That forecast is now at a critical point, with the expectation of significant revenue by mid year. If real world results deviate, and the FY17/18E result is way off the mark, I'll be out, and I anticipate an exodus of others also, as for me at least, that would be a catastrophic outlook for the company and its potential existence.

If it doesn't perform, then after 13 years(Founded 2004), OBJ cant say it hasn't had AMPLE and abundant time to perform. It would be absurd and ridiculous to think any new company/startup may need 15+ years just to be in positive cash flow. It has to start making money, that's the purpose of being in business, otherwise it should relist as a charity.

Revenue Forecast from B&Y Feb 2016


Of course this is all IMO, lets wait and see what eventuates.